Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
CFZ533 - Blocking, non-depleting, Fc-silent, anti-CD40
monoclonal antibody
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT03781414 CONTRAIL I (CCFZ533A2202)
Liver transplantation
Phase 2
128
Proportion of patients with composite event (BPAR, Graft Loss or Death) over 12
months
Control/Standard of Care: TAC + MMF + Corticosteroids
CFZ533 dose A+ MMF + Corticosteroids
CFZ533 dose B + MMF + Corticosteroids
Target Patients
Liver transplant recipients
Read-out Milesstone(s)
2023
Publication
2023
71 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation